Concord Biotech Limited has announced the receipt of Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (USFDA) for its Mycophenolate Mofetil for Oral Suspension USP, 200 mg/mL. According to the company's announcement, this regulatory milestone represents a significant development for the pharmaceutical company's US market expansion strategy and marks a key achievement in the highly competitive pharmaceutical landscape. Concord Biotech shares surged as much as 8.46% on Wednesday, hitting an intraday high of ₹1,264.90, following the announcement of this approval. The company highlighted that the approval aligns with its long-term growth strategy and is expected to strengthen its presence in the U.S. pharmaceutical market.
The approved product is a Mycophenolate Mofetil oral suspension formulated at 200 mg/mL concentration. As reported by Concord Biotech Limited, this oral suspension formulation provides a convenient administration option for patients requiring immunosuppressant therapy. Mycophenolate Mofetil is classified as an antimetabolite immunosuppressant with specific indications for the prophylaxis of organ rejection in adult and pediatric patients. According to the regulatory approval, the drug is indicated for patients 3 months of age and older who have undergone allogeneic kidney, heart, or liver transplants, when used in combination with other immunosuppressants. The medication is administered in combination with other immunosuppressive therapies.
Industry estimates suggest that the U.S. market for Mycophenolate Mofetil is valued at approximately US$30 million, providing Concord Biotech with a significant commercial opportunity. The company noted that the approval will enhance its product portfolio and support expansion across both U.S. and international markets. There were no instances of withdrawal, cancellation, or suspension of the approval, and therefore no associated penalties or adverse financial impact. The approval positions the company to enter the US transplant immunosuppressant market with a generic version of this important medication.
The stock is trading at a price-to-earnings (P/E) ratio of 42.56 and a price-to-book (P/B) ratio of 6.13. The market capitalisation of Concord Biotech stands at ₹12,206.62 crore. The stock has shown significant volatility with a 52-week high of ₹2,149.90 and a 52-week low of ₹987.05. Currently, the stock is trading 45.73% below its 52-week high and 18.21% above its 52-week low, indicating recent recovery from lower levels. The company's shares are expected to remain in focus following this regulatory approval, which positions it to enter the US transplant immunosuppressant market with a generic version of this important medication.
